

12 June 2013

'RESEARCH NEVER STOPS'

info@evotec.com | www.evotec.com

For further information,
please contact

Gabriele Hansen
Head of Corporate Communications
+49.(0)40.560 81-255
+49.(0)40.560 81-222 Fax
gabriele.hansen@evotec.com

Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)

Resolutions of the Annual General Meeting of Evotec AG

- **Actions of Management Board and Supervisory Board approved**
- **Dr Walter Wenninger becomes new Chairman of the Supervisory Board**
- **Dr Claus Braestrup elected as new member of the Supervisory Board**
- **Fixed remuneration for the Supervisory Board concluded**

Hamburg – 12 June 2013: Shareholders of Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting.

The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented the Company's performance for the year 2012 and provided the shareholders with an update on the topic innovation efficiency within Action Plan 2016.

Furthermore, the Annual General Meeting elected Dr Claus Braestrup as new member of the Supervisory Board. Dr Braestrup has extensive experience in executive-level functions at international pharmaceutical companies – among others as former President and CEO and Head of Research and Development of Lundbeck A/S and as Vice President for pharmaceutical research at Novo Nordisk A/S. His special skills in the area of drug research are of great value for his task within the Supervisory Board.

Dr Braestrup succeeds Dr Flemming Ørnskov until the completion of the Annual General Meeting 2014. Dr Ørnskov resigned as member and Chairman of the Supervisory Board upon conclusion of the Annual General Meeting 2013. In a subsequent meeting of the Supervisory Board, Dr Walter Wenninger, former Deputy Chairman of the Supervisory Board, was elected as Chairman of the Supervisory Board and Mr Roland Oetker was elected as his Deputy Chairman.

"I'd like to express my sincere gratitude to Dr Ørnskov, also on behalf of my colleagues in the Management Board, for his constructive and successful collaboration over the last years. We wish him all the best for realising his professional and personal objectives", **said Dr Werner Lanthaler, Chief Executive Officer of Evotec.** "At the same time, I'd like to warmly welcome Dr Claus Braestrup to the Evotec Supervisory Board."

The Annual General Meeting also approved the proposal of the Management Board and the Supervisory Board to change the remuneration of the Supervisory Board to a fixed remuneration in form of cash compensation from fiscal year 2013 onwards. Moreover, the Annual General Meeting passed all of the other agenda items

requiring shareholders' approval, thereunder the resolution on single amendments of the articles of association and the appointment of KPMG as the auditor for fiscal year 2013.

At the ordinary Annual General Meeting 2013 of Evotec AG, 40.5% of the voting capital was present.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS — *Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.*